Pennsylvania’s Department of Health established the Medical Marijuana Act on April 17, 2016. In it were regulations aimed at protecting consumers which require all final products to undergo rigorous testing by third-party laboratories.
US Cannalytics was formed to serve the industry and patients of Pennsylvania. Our backgrounds in chemistry, microbiology, health care, and laboratory operations enable us to execute at an industry-leading level, while utilizing the latest technology and ISO-accredited methodology.
US Cannalytics received its ISO/IEC 17025:2017 certification for chemical testing by A2LA on January 23rd, 2020. The Pennsylvania Department of Health granted US Cannalytics its license to operate on February 7th, 2020. We are honored and grateful to participate in this burgeoning industry!
